2076975 2077203
최종편집 2024-05-20 21:02 (월)
AstraZeneca Tagrisso approves by HIRA
상태바
AstraZeneca Tagrisso approves by HIRA
  • Hyeokgi Lee, Newsmp
  • 승인 2023.03.28 21:18
  • 댓글 0
이 기사를 공유합니다

[Newsmp] The Cancer Diseases Deliberation Committee has given its approval for AstraZeneca’s anticancer drug Tagrisso.

On March 22, the Health Insurance Review and Assessment Service (HIRA) disclosed the results of its 2nd Cancer Diseases Deliberation Committee.

During the meeting, two drugs, Tagrisso (AstraZeneca) and Darzalex (Janssen) were reviewed.

Tagrisso (ingredient: Osimertinib) obtained reimbursement expansion and standards by demonstrating efficacy and effectiveness as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

Janssen Korea’s Darzalex (ingredient: Daratumumab) applied for reimbursement expansion based on its efficacy in combination with lenalidomide and dexamethasone, bortezomib and dexamethasone, and carfilzomib and dexamethasone for multiple myeloma patients who have received one or more prior therapies but did not pass the Cancer Diseases Deliberation Committee's evaluation for all three efficacy and effects.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.